Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.0052W HIGH $28.23
Volume
154.20 K
Value Traded
23.16 M
Short % Float
18.19%
-3.39%Week
-15.42%1 Month
-3.69%3 Month
+38.55%6 Month
-30.28%5 Year
-3.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.24 B
EPS (TTM)
-3.29
P/E Ratio
-
Ent. Value
1.86 B
Total Shares
103.76 M
Float Shares
98.84 M
Insiders
4.76%
Institutions
110.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NRIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Nurix Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nurix Therapeutics, Inc.
399Total events
10Upcoming
45Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 50
▲First Patient DosedNX-5948Trial
First patient enrolled in Phase 1b/2 NX-5948-203 study of bexobrutideg plus venetoclax in CLL/SLL
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
▲Trial InitiationNX-5948Trial
Initiation of Phase 1b/2 NX-5948-203 combination study of bexobrutideg with venetoclax
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
▲Milestone PaymentCorporate
Nurix to receive $10 million research term extension fee from Gilead
undisclosed oncology programsource ↗
▲Partnership / LicenseCorporate
Nurix and Gilead extend research term for undisclosed oncology program by two years
undisclosed oncology programsource ↗
▲Milestone PaymentCorporate
Nurix receives $7 million research milestone payment from Pfizer under DAC collaboration
▲First Patient DosedNX-5948Trial
First patient enrolled in Phase 3 DAYBreak CLL-306 trial
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
▲Milestone PaymentCorporate
Nurix earns $10 million milestone payment from Sanofi for STAT6 degrader Phase 1 initiation
▲Trial InitiationTrial
Phase 1 clinical trial of oral STAT6 degrader initiated
type 2 inflammatory diseasessource ↗
▲Codev CocommercialNX-5948Corporate
HSR clearance and closing of global collaboration with Roche to co-develop and co-commercialize bexobrutideg
malignant hematology, immunology, neurologysource ↗
▲Partnership / LicenseNX-5948Corporate
Global collaboration with Roche for bexobrutideg
malignant hematology, immunology, neurologysource ↗
◆Enrollment UpdateNX-5948Trial
Enrollment continues in pivotal Phase 2 trial
relapsed/refractory CLLsource ↗
▲Enrollment CompleteNX-1607Trial
Completed enrollment in Phase 1a dose escalation cohorts
solid tumorssource ↗
▲Enrollment CompletezelebrudomideTrial
Completed enrollment in Phase 1 dose escalation cohorts
relapsed/refractory B-cell malignanciessource ↗
◆IND Enabling CompleteNX-3911Preclinical
Sanofi advancing STAT6 degrader in IND-enabling studies
▲Oral PresentationNX-5948Presentation
Updated Phase 1a/b results for bexobrutideg in R/R CLL/SLL presented at EHA 2026
chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
▲Trial InitiationNX-5948Trial
Pivotal Phase 2 trial DAYBreak CLL-201 initiated
relapsed/refractory CLLsource ↗
▲Partnership / LicenseNX-5948Corporate
Roche and Nurix enter exclusive licensing and collaboration agreement for bexobrutideg
B-cell malignancies, chronic spontaneous urticaria, multiple sclerosissource ↗
▲Partnership / LicenseNX-5948Corporate
Global collaboration with Roche to co-develop and co-commercialize bexobrutideg
malignant hematology, immunology, neurologysource ↗
▲Oral PresentationNX-5948Presentation
Clinical data update at EHA 2026
relapsed/refractory CLL/SLLsource ↗
▲Timing GuidancePresentation
Nurix eligible for up to approximately $1.3 billion in total payments under Gilead collaboration
oncology and inflammatory diseasessource ↗
◆Oral PresentationPresentation
Oral presentation: Designing Effective Degrader Therapeutics: What Early Clinical Experience Has Taught Us by Gwenn Hansen
◆Oral PresentationPresentation
Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growth
cancersource ↗
◆Poster PresentationNRX-4972PreclinicalPresentation
Poster: NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model
SCLCsource ↗
◆Poster PresentationNRX-0305PreclinicalPresentation
NRX-0305 is an orally bioavailable, pan-mutant BRAF degrader that exhibits single-agent and combination efficacy with MEKi or anti-EGFR across Class 1/2/3 BRAF-mutant cancers
BRAF-mutant cancerssource ↗
◆Enrollment CompleteNX-5948Trial
Enrollment ongoing in Phase 2 DAYBreak CLL-201 trial
relapsed refractory chronic lymphocytic leukemiasource ↗
◆Trial InitiationNX-5948Trial
Initiation of Phase 3 confirmatory trial by midyear 2026
relapsed refractory chronic lymphocytic leukemiasource ↗
●Enrollment CompleteNX-1607Trial
Completed enrollment of current Phase 1a dose escalation cohorts
solid tumorssource ↗
●Enrollment CompletezelebrudomideTrial
Completed enrollment in current dose escalation cohorts
B-cell malignanciessource ↗
▲First Patient DosedNX-5948Trial
First patient dosed anticipated in mid-2026
relapsed/refractory CLLsource ↗
▲Oral PresentationNX-5948Presentation
Oral presentation of Phase 1 data for bexobrutideg in WM at ASH 2025
Waldenström macroglobulinemiasource ↗
▲Trial InitiationNX-5948Trial
Phase 2 pivotal trial DAYBreak-CLL-201 currently enrolling globally
relapsed or refractory chronic lymphocytic leukemia (CLL)source ↗
▲Oral PresentationNX-5948Presentation
Oral presentation of Phase 1a/1b data at ASH 2025
relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)source ↗
◆Poster PresentationPresentation
Poster presentation on molecular basis of pan-resistance to BTK therapies at ASH 2025
BTK resistancesource ↗
▲Oral PresentationNX-5948Presentation
Phase 1 results presented at ASH 2025 for bexobrutideg in CLL
relapsed/refractory CLLsource ↗
▲First Patient DosedNX-5948Trial
First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL
relapsed/refractory CLLsource ↗
●Oral PresentationGS-6791Presentation
Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead
▲Poster PresentationNX-1607Presentation
Presentation of translational data from Phase 1 study of NX-1607 at SITC 2025
advanced solid tumorssource ↗
▲Poster PresentationNX-1607Presentation
Translational data for NX-1607 presented at SITC 2025
solid tumorssource ↗
▼Equity OfferingCorporate
Pricing of $250.0 million registered offering of common stock at $10.21 per share
Past FDA Catalysts and PDUFA Decisions
How NRIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-21 | NRX-4972 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$254M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 57%
Small Cap(rank 375 of 658)
Percentile Rank
Nurix Therapeutics, Inc. faces pipeline headwinds (34/100), with $540M risk-adjusted pipeline value, led by NX-5948 in B-cell Lymphoma (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NX-5948 Small moleculeNCT07520006 | B-cell Lymphoma | Phase 3 | RECRUITING | 770 | May 1, 2033 |
Clinical Trial Results
Readouts, endpoints and source filings for every NRIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| bexobrutideg Orphan | chronic lymphocytic leukemia (CLL) | Phase 1a/1b | 2026-06-11 | objective response rate: 92.9%; median progression free survival: 22.1 months; objective response rate heavily pretreated: 83%; treatment discontinuations due to adverse events: 5.6%Read More | Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ring ChristineOfficer (Chief Legal Officer) | Option | 5,786 14,896 held | $8.72 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NRIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.7 % (68.8 %) | 187.69 M | 7.74 M | 21.93% ( 1.39 M) |
NRIX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NRIX ranks across every disease it competes in
Competitive Position is a premium feature
See how NRIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNRIX News
NRIX▼ -1.5%today
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax for chronic lymphocytic leukemia (CLL). This study aims to assess the safety and efficacy of this combination therapy, which may expand into other B-cell malignancies. The collaboration with Roche is expected to enhance the development of bexobrutideg across various treatment lines.
Read more →NRIXNurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics has announced a two-year extension of its research collaboration with Gilead Sciences for an undisclosed oncology program. This marks the second extension since their partnership began in 2019. Nurix will receive a $10 million fee for this extension and retains co-development and profit-sharing rights on up to two programs in the U.S.
Read more →NRIXNurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Nurix Therapeutics has achieved a $7 million milestone under its collaboration with Pfizer, bringing total payments to $82 million. The partnership focuses on developing degrader antibody conjugates (DACs), which combine the selectivity of antibodies with targeted protein degradation. This innovative approach aims to enhance treatment options for cancer and autoimmune diseases.
Read more →NRIXNurix Therapeutics to Participate in Upcoming September Investor Conferences
Nurix Therapeutics announced its participation in several upcoming investor conferences in September 2026. The events include fireside chats at notable conferences such as Wells Fargo and H.C. Wainwright. These discussions will be accessible via live webcasts and archived for 30 days, highlighting the company's commitment to transparency and investor engagement.
Read more →NRIXNurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has appointed Wes Burwell as Chief Human Resources Officer. Burwell will be a key member of the Executive Management Team, leading HR as the company advances its clinical pipeline and prepares for commercialization. His extensive experience in scaling organizations will support Nurix's growth as it transitions into a fully integrated biopharmaceutical company.
Read more →NRIX▲ +6.3%on this news
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Nurix has announced the initiation of a Phase 1 clinical trial for its oral STAT6 degrader, aimed at treating type 2 inflammatory diseases. The company has generated about $139 million from its collaboration with Sanofi and is poised to receive up to $453 million in future milestone payments related to the STAT6 program.
Read more →NRIX▲ +6.3%on this newsshared move
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics has enrolled the first patient in its Phase 3 DAYBreak CLL-306 trial, evaluating bexobrutideg for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial aims to compare bexobrutideg with the current standard of care, pirtobrutinib. The study is significant as it marks the first Phase 3 trial for this investigational drug.
Read more →NRIXNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics has announced the closing of a global collaboration with Roche to co-develop and commercialize bexobrutideg, a novel BTK degrader. The agreement includes a $700 million upfront payment and potential total payments of up to $2.3 billion. The collaboration aims to address unmet medical needs in oncology, immunology, and neurology through a comprehensive clinical development program.
Read more →NRIX▼ -6.6%on this news
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics reported its Q2 2026 financial results, highlighting a global collaboration with Roche for bexobrutideg, which includes a $700 million upfront payment. The partnership aims to co-develop the drug across multiple indications, including chronic lymphocytic leukemia and autoimmune diseases. Clinical data presented at the European Hematology Association supports its potential as a leading BTK degrader. Despite a net loss of $89.5 million, Nurix remains well-capitalized with significant cash reserves.
Read more →NRIX▲ +11%on this news
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics announced updated Phase 1a/b results for bexobrutideg, showing a high objective response rate of 92.9% in second-line patients with chronic lymphocytic leukemia (CLL) who progressed on a BTK inhibitor. The drug demonstrated a median progression-free survival of 22.1 months in heavily pretreated patients. The findings will be presented at the 2026 EHA Congress, highlighting its potential as a best-in-class treatment.
Read more →NRIX▲ +11%on this newsshared move
Nurix Therapeutics to Report Updated Phase 1a b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed Refractory CLL SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics has announced updated results from its Phase 1a b trial for bexobrutideg, reporting a high response rate and promising activity in earlier lines of therapy for chronic lymphocytic leukemia (CLL). The trial demonstrated a 92.9% response rate in patients who had previously progressed on BTK inhibitors, alongside a median progression-free survival of 22.1 months in heavily pretreated patients. The safety profile remains favorable, and the drug appears effective even in complicated cases with high-risk features. These findings will be presented at the 2026 European Hematology Association Congress.
Read more →NRIX▲ +6.8%on this newsshared move
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Read more →NRIX▲ +6.8%on this newsshared move
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, a novel BTK degrader aimed at treating B-cell malignancies, immunological conditions, and neurological disorders. The agreement includes a significant upfront payment and shared development costs, with Roche leading commercialization efforts. Bexobrutideg is expected to enter Phase 3 trials in summer 2026, potentially offering improved efficacy over existing therapies.
Read more →NRIXNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Read more →NRIXNurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Read more →NRIXNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
Nurix Therapeutics has announced that an abstract detailing updated efficacy and safety data from the Phase 1a/b trial of its BTK degrader, bexobrutideg (NX-5948), has been accepted for oral presentation at the 2026 European Hematology Association Congress. The presentation is scheduled for June 14, 2026, in Stockholm, Sweden, highlighting its potential in treating chronic lymphocytic leukemia.
Read more →NRIXNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Read more →NRIXNurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported its financial results for the first quarter of 2026, highlighting ongoing developments in its pipeline. The company is actively enrolling patients in the Phase 2 DAYBreak CLL-201 trial for bexobrutideg, targeting relapsed refractory chronic lymphocytic leukemia, and preparing for a Phase 3 trial slated for mid-2026. Despite a notable reduction in revenue and a significant net loss compared to the previous year, Nurix maintains a healthy cash position and is exploring additional indications for its investigational drug, all while leveraging strategic partnerships.
Read more →About Nurix Therapeutics, Inc.
Headquarters1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE PLUS
Trade the next NRIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime